Medtronic Rolls Out Newest CRT-P Device in Europe

Medtronic Thursday announced the European launch of the Viva cardiac resynchronization therapy-pacemaker, following CE marking.

The device will be available this month in the UK, Ireland, Norway, Switzerland and the Netherlands, with Germany to follow next month, said company spokeswoman Tracy McNulty. Plans are to continue the rollout throughout the summer and have Viva CRT-P in a majority of EU markets by later this year, she added.

Viva CRT-P uses Medtronic’s AdaptivCRT software algorithm to customize patient therapy and preserve normal heart rhythms by continuously adjusting to the patient’s needs. The system also features advanced diagnostic tools that monitor and record the patients’ physiological condition, allowing patients who are at risk for rehospitalization within 30 days to be identified, the company said.

“The diagnostic capabilities of this smart device help improve function throughout the continuum of care,” said David Steinhaus, vice president and general manager, Heart Failure, and medical director for Medtronic’s Cardiac Rhythm Disease Management business.

Viva CRT-P is not yet approved in the U.S. McNulty said a premarket approval application for the device has been submitted to the FDA. — Meg Bryant

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.